Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Chemotherapy-induced nausea and vomiting
Cisplatin
Dexamethasone
Netupitant
Palonosetron
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
25
02
2021
accepted:
25
05
2021
pubmed:
9
6
2021
medline:
26
10
2021
entrez:
8
6
2021
Statut:
ppublish
Résumé
To reduce the overall exposure to dexamethasone (DEX) in patients receiving cisplatin-based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or without low-dose DEX on days 2 and 3, combined with an oral fixed-dose combination of netupitant and palonosetron (NEPA), compared with the guideline-consistent use of 4-day DEX. In this open-label, multicenter study, chemotherapy-naïve patients undergoing high-dose cisplatin (≥70 mg/m Two-hundred twenty-eight patients, 76 in each arm, were assessable. Noninferiority was met for both DEX-sparing regimens and the reference arm, with overall phase CR rates of 76.3% in each of the DEX1 and DEX3 arms and 75.0% in the DEX4 arm (95% confidence interval, -12.3% to 15% for each comparison). During the overall phase, CP rates were similar between groups. A simplified regimen of NEPA plus single-dose DEX offers comparable chemotherapy-induced nausea and vomiting prevention throughout 5 days post-chemotherapy with the advantage of sparing patients additional doses of DEX in the high-emetic-risk setting of cisplatin-based chemotherapy. Dexamethasone (DEX) has traditionally played an integral role in the management of chemotherapy-induced emesis. Although generally considered safe, even short-term DEX use is associated with various side effects, and some evidence suggests that concurrent steroids may reduce the efficacy of immunotherapies. This study demonstrates comparable antiemetic control during the 5 days post-chemotherapy with a simplified regimen of netupitant/palonosetron plus single-dose DEX versus the standard 4-day DEX reference treatment in high-dose cisplatin. This represents a clinically relevant achievement as it not only simplifies antiemetic prophylaxis but also offers an opportunity to appropriately use in patients where caution with corticosteroid use is advised.
Sections du résumé
BACKGROUND
To reduce the overall exposure to dexamethasone (DEX) in patients receiving cisplatin-based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or without low-dose DEX on days 2 and 3, combined with an oral fixed-dose combination of netupitant and palonosetron (NEPA), compared with the guideline-consistent use of 4-day DEX.
PATIENTS AND METHODS
In this open-label, multicenter study, chemotherapy-naïve patients undergoing high-dose cisplatin (≥70 mg/m
RESULTS
Two-hundred twenty-eight patients, 76 in each arm, were assessable. Noninferiority was met for both DEX-sparing regimens and the reference arm, with overall phase CR rates of 76.3% in each of the DEX1 and DEX3 arms and 75.0% in the DEX4 arm (95% confidence interval, -12.3% to 15% for each comparison). During the overall phase, CP rates were similar between groups.
CONCLUSION
A simplified regimen of NEPA plus single-dose DEX offers comparable chemotherapy-induced nausea and vomiting prevention throughout 5 days post-chemotherapy with the advantage of sparing patients additional doses of DEX in the high-emetic-risk setting of cisplatin-based chemotherapy.
IMPLICATIONS FOR PRACTICE
Dexamethasone (DEX) has traditionally played an integral role in the management of chemotherapy-induced emesis. Although generally considered safe, even short-term DEX use is associated with various side effects, and some evidence suggests that concurrent steroids may reduce the efficacy of immunotherapies. This study demonstrates comparable antiemetic control during the 5 days post-chemotherapy with a simplified regimen of netupitant/palonosetron plus single-dose DEX versus the standard 4-day DEX reference treatment in high-dose cisplatin. This represents a clinically relevant achievement as it not only simplifies antiemetic prophylaxis but also offers an opportunity to appropriately use in patients where caution with corticosteroid use is advised.
Identifiants
pubmed: 34101934
doi: 10.1002/onco.13851
pmc: PMC8488764
doi:
Substances chimiques
Antiemetics
0
Pyridines
0
Quinuclidines
0
Palonosetron
5D06587D6R
netupitant
7732P08TIR
Dexamethasone
7S5I7G3JQL
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1854-e1861Informations de copyright
© 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Références
Ann Oncol. 2010 May;21(5):1083-8
pubmed: 20080830
Ann Oncol. 2015 Jun;26(6):1081-1090
pubmed: 25755107
Cancer Res Treat. 2016 Oct;48(4):1429-1437
pubmed: 26987397
Br J Cancer. 2006 Apr 10;94(7):1011-5
pubmed: 16552437
Ann Oncol. 2014 Jul;25(7):1340-1346
pubmed: 24608196
J Clin Oncol. 2018 Sep 10;36(26):2741-2742
pubmed: 29799771
Oncologist. 2017 May;22(5):592-600
pubmed: 28341762
Ann Oncol. 2014 Jul;25(7):1328-1333
pubmed: 24603643
Oncologist. 2015 Dec;20(12):1432-9
pubmed: 26463869
Ann Oncol. 2016 Sep;27(suppl 5):v119-v133
pubmed: 27664248
Lancet Oncol. 2020 Feb;21(2):242-249
pubmed: 31838011
Tumori. 2008 Jul-Aug;94(4):447-52
pubmed: 18822676
Ann Oncol. 2012 Aug;23(8):1986-1992
pubmed: 22396444
Ann Oncol. 2018 Feb 1;29(2):452-458
pubmed: 29092012
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
BMC Cancer. 2019 Dec 30;19(1):1268
pubmed: 31888544
J Clin Oncol. 2018 Apr 1;36(10):1000-1006
pubmed: 29443652
Ann Oncol. 2007 Feb;18(2):233-40
pubmed: 17108149